Biotic Ingredients Market

Market Snapshot

• The biotic ingredients market size is USD 7.81 Billion in 2025, reached USD 8.49 Billion in 2026, and is projected to hit USD 17.72 Billion by 2035 at a CAGR of 8.5%.
• Bacterial Probiotics is projected to hold the dominant type segment with a 66.3% revenue share in 2026.
• Powders is anticipated to lead the By Form segment with a 55.2% revenue share in 2026.
• Asia-Pacific is projected to hold the dominant regional position in 2026 with 43.1% of market share.
• Key applications include Functional Food and Beverages, Dietary Supplements, Infant Nutrition, Medical Food, Pharmaceuticals, and Personal Care and Beauty Products.

Market Overview

The global biotic ingredients market encompasses the production and commercial supply of bacterial probiotics, yeast probiotics, prebiotics, and postbiotics deployed across functional food and beverage, dietary supplement, infant nutrition, medical food, pharmaceutical, and personal care applications. The sector was valued at USD 7.81 Billion in 2025 and spans multiple manufacturing technologies including fermentation, encapsulation, drying and stabilization, centrifugation and filtration, and cell disruption serving both human and emerging animal health end-use channels.

Consumer behavior is fundamentally reshaping the commercial boundaries of this market. Biotic ingredients are no longer confined to digestive health supplements. Buyers and formulators now source these inputs for immune health, brain health, metabolic health, beauty-from-within, sports nutrition, and women's health applications. This broadening of validated health benefit claims has extended biotic ingredient demand into personal care and cosmeceutical formulations, materially widening the total addressable market beyond traditional food and pharmaceutical channels.

Key Statistics

Corporate Performance

• According to Kirin Holdings, the company recorded total annual net sales of JPY 23.0 Billion from its LC-Plasma postbiotic ingredient segment in FY2024, representing a 10.0% increase year-on-year in February 2025.
• According to Kirin Holdings, overseas sales volume of LC-Plasma postbiotic ingredients expanded by more than 200.0% year-on-year in FY2024, primarily driven by industrial raw material sales in February 2025.
• According to Kirin Holdings, the company achieved total annual sales exceeding JPY 28.0 Billion from its L. lactis strain Plasma postbiotic series in FY2025, announced in February 2026.
• According to Novonesis, the company delivered 5.0% organic sales growth within its Human Health biotic segment in FY2024, reported in February 2025.
• According to Novonesis, emerging markets registered 12.0% organic sales growth across its biosolutions portfolio during FY2024, as announced in February 2025.
• According to Novonesis, the company generated 7.0% broad-based organic sales growth across total operations in FY2025, while achieving an adjusted EBITDA margin of 37.1% in February 2026.

Consumer Awareness

• According to Frontiers in Immunology, 84.1% of 1,306 adult respondents believed biotic ingredients actively support digestion and gastrointestinal health in October 2024.
• According to Frontiers in Immunology, 72.5% of 1,306 surveyed adults associated regular prebiotic or probiotic use with immune system support in October 2024.
• According to Kirin Holdings, over 70.0% of 635 respondents reported increased awareness of daily health management throughout the year in February 2026.
• According to the 2025 Market Survey, 51.8% of surveyed adults in Saudi Arabia rated their probiotic knowledge as low, highlighting significant consumer education opportunities.

Public Sector Investment

• According to ACS Biomaterials, the National Institutes of Health allocated USD 215.0 Million to the Human Microbiome Project to investigate health outcomes linked to microbiota variation in December 2021.

Market Size and Forecast

The Global Biotic Ingredients Market size is projected to be valued at USD 8.49 Billion in 2026 from USD 7.81 Billion in 2025, and is projected to reach USD 17.72 Billion by 2035, exhibiting a CAGR of 8.5% during the forecast period.

The forecast rests on three structural forces: widening health benefit adoption across non-digestive categories, accelerating B2B ingredient supply expansion by major biosolution companies, and rising consumer health awareness converting casual buyers into habitual users. Novonesis reporting an 8.0% organic growth rate in its Food and Health division in FY2025 confirms that leading suppliers are already capturing this trajectory. The consistent double-digit overseas volume expansion by ingredient manufacturers signals that international demand is absorbing new supply without pricing pressure, which supports the durability of the 8.5% growth rate through 2035.

Market Dynamics

Market Drivers

Mainstream Consumer Health Spending Expands Biotic Ingredient Demand
The global biotic ingredients market is being strongly driven by rising consumer spending on preventive health and wellness products. Consumers are increasingly purchasing probiotics, prebiotics, postbiotics, and synbiotics to support digestive health, immunity, metabolism, and overall wellbeing. This behavioral shift has transformed biotic ingredients from a niche supplement category into a mainstream component of foods, beverages, dietary supplements, and personal care products. Large multinational companies are accelerating investments to capture this demand. PepsiCo's USD 1.95 billion acquisition of prebiotic soda brand Poppi in 2025 reflects growing commercial interest in gut-health beverages, while Danone's acquisition of The Akkermansia Company highlights competition for next-generation microbiome technologies. Expanding product innovation, rising health awareness, and increasing functional food consumption continue to strengthen long-term demand for biotic ingredients globally.

Expanding Functional Food and Beverage Industry Accelerates Market Growth
The rapid expansion of the functional food and beverage industry is significantly accelerating growth in the global biotic ingredients market. Consumers increasingly prefer products offering scientifically supported health benefits, encouraging manufacturers to incorporate probiotics, prebiotics, and synbiotics into dairy products, beverages, snacks, and nutritional supplements. Companies are actively launching clinically backed formulations targeting digestive health, immunity, mental wellness, and metabolic support. Growing urbanization, changing dietary habits, and rising disposable incomes are further supporting premium functional nutrition demand across developed and emerging economies. Retail channels and e-commerce platforms are also improving accessibility to biotic-based products globally.

Market Restraints

Regulatory Complexity Slows Commercialization of Advanced Biotic Products
Stringent regulatory requirements remain a major restraint in the global biotic ingredients market, particularly for products targeting mental health and specialized therapeutic applications. Psychobiotic products designed to support cognitive and emotional wellness require extensive randomized placebo-controlled clinical trials before companies can make approved health claims. These demanding approval standards significantly increase research costs, prolong commercialization timelines, and create barriers for smaller biotechnology firms. Many emerging companies lack the financial resources required to conduct large-scale clinical studies, forcing them to seek partnerships or delay product launches. Regulatory differences between countries further complicate international expansion strategies for ingredient suppliers and consumer brands. In addition, increasing scrutiny over health claims, labeling transparency, and microbiome efficacy data is intensifying compliance requirements. These regulatory pressures continue to slow innovation speed and market entry for advanced biotic formulations globally.

Strain Stability and Formulation Challenges Limit Product Flexibility
Technical challenges related to microbial strain stability and formulation complexity are limiting growth opportunities within the global biotic ingredients market. Yeast-based biotics, in particular, face difficulties associated with lower strain diversity, reduced formulation flexibility, and comparatively weaker clinical backing than bacterial probiotics. Bacterial probiotics accounted for a dominant market share because they offer broader strain diversity, stronger scientific validation, and greater compatibility across food, beverage, and supplement applications. Maintaining microbial viability during processing, storage, and transportation also remains a major challenge for manufacturers.

Market Opportunities

Geriatric Nutrition Creates High-Value Growth Opportunities
The growing aging population worldwide is creating significant opportunities for the global biotic ingredients market, particularly in geriatric nutrition and healthy aging applications. Older consumers are increasingly seeking preventive healthcare products that support digestive function, muscle health, immunity, and metabolic wellness. Companies are responding by launching clinically validated biotic formulations specifically designed for aging populations. Lallemand Health Solutions introduced its Cerenity probiotic blend targeting the gut-muscle axis in 2025, reflecting rising commercial focus on healthy aging nutrition. Developed economies with aging demographics present especially attractive markets because elderly consumers generally possess higher healthcare spending capacity and stronger interest in wellness-oriented products.

Pet Nutrition and Cosmeceuticals Expand New Industrial Demand
The emergence of pet nutrition and microbiome-based beauty products is opening entirely new revenue streams within the global biotic ingredients market. Companion animal humanization trends are increasing demand for premium pet supplements targeting digestive, oral, and immune health. In 2025, Probi introduced specialized probiotic formulations for pet digestive and oral care, demonstrating growing industry interest in animal wellness applications. Simultaneously, cosmetic manufacturers, particularly in South Korea, are integrating postbiotic and microbiome-supporting ingredients into skincare and anti-inflammatory dermo-cosmetic products. Consumers increasingly associate skin health with microbiome balance, creating demand for scientifically backed beauty-from-within and topical biotic formulations.

Market Trends

Synbiotic Formulations Replace Single-Ingredient Products
One of the most significant trends in the global biotic ingredients market is the transition from single-strain products toward advanced synbiotic formulations combining probiotics and prebiotics for enhanced clinical effectiveness. Companies increasingly compete based on scientifically validated health outcomes rather than standalone ingredient performance. In 2024, Probi and Clasado launched commercial synbiotic formulations combining Bimuno GOS prebiotics with Defendum probiotics, reflecting the market's shift toward combination therapies with targeted functionality. Consumers and healthcare providers are increasingly demanding products supported by stronger efficacy data for digestive health, immunity, and metabolic wellness. This trend is encouraging ingredient manufacturers to invest heavily in microbiome science, clinical validation, and personalized nutrition technologies. As competition intensifies, companies offering clinically differentiated multi-ingredient formulations are expected to secure stronger B2B partnerships and premium positioning across global functional nutrition markets.

Precision Strain Development Gains Competitive Importance
Precision strain development is becoming a major competitive trend within the global biotic ingredients market as companies focus on condition-specific microbiome solutions. Manufacturers are increasingly developing targeted bacterial strains designed for highly specialized applications including inflammatory bowel disease, pediatric nutrition, metabolic disorders, mental health, and immune support. PharmExtracta's launch of Colipral and Brevicillin bacterial strain formulations for ulcerative colitis and pediatric applications at CPHI 2025 highlights this growing focus on precision microbiome therapies. Companies are investing in genomic analysis, microbiome sequencing, and clinical research to establish differentiated strain-specific efficacy claims. This precision-based approach allows suppliers to create stronger intellectual property protection, secure long-term B2B supply agreements, and achieve premium pricing strategies. As scientific understanding of the microbiome expands, precision strain innovation is expected to become a key market differentiator globally.

By Form Analysis

Powders is projected to account for 55.2% of the By Form segment in 2026, driven by their compatibility with bulk B2B ingredient blending, long shelf life, and cost efficiency in large-scale food and supplement manufacturing. For ingredient buyers formulating functional foods and infant nutrition products, powders offer the lowest processing friction of any delivery format.

Granules, capsules, and liquids each address specific end-use constraints that powders cannot fully serve. Capsules dominate in pharmaceutical and clinical nutrition channels where precise dosing and gut-targeted delivery are required. Liquids hold ground in ready-to-drink functional beverages, a channel that PepsiCo's USD 1.95 billion Poppi acquisition confirms is attracting major investment. Granules serve niche applications in pediatric and elderly nutrition where swallowability and dispersibility matter. The diversification of form factor demand signals that suppliers capable of offering multi-format strain delivery will capture a wider slice of B2B contracts.

Key Market Segments

By Type

• Bacterial Probiotics
• Yeast Probiotics
• Prebiotics
• Postbiotics

By Form

• Powders
• Granules
• Capsules/Tablets
• Liquids

By Strain

• Lactobacillus
• Bifidobacterium
• Saccharomyces
• Bacillus
• Streptococcus
• Others

By Manufacturing Technology

• Fermentation
• Centrifugation & Filtration
• Drying & Stabilization
• Encapsulation & Protection Technologies
• Inactivation & Cell Disruption

By Application

• Functional Food & Beverages
  • Probiotic Yogurt
  • Fermented Dairy Products
  • Functional Beverages
  • Kombucha & Fermented Drinks
  • Fortified Snacks & Cereals
  • Plant-Based Functional Foods
• Dietary Supplements
  • Capsules & Tablets
  • Powder Supplements
  • Gummies
  • Sachets & Stick Packs
  • Liquid Supplements
• Infant Nutrition
  • Infant Formula
  • Baby Food Products
  • Pediatric Nutritional Supplements
  • Synbiotic Infant Products
• Medical Foods
  • Clinical Nutrition Products
  • Digestive Health Formulations
  • Enteral Nutrition
  • Disease-Specific Nutritional Products
• Pharmaceuticals
  • Gastrointestinal Therapeutics
  • Immune Support Products
  • Antibiotic-Associated Diarrhea Treatments
  • Women's Health Probiotics
  • Prescription Microbiome Therapies
• Personal Care & Beauty Products
  • Skincare Products
  • Anti-Aging Formulations
  • Acne Care Products
  • Scalp & Hair Care Products
  • Beauty-from-Within Supplements
  • Microbiome Beauty Products
• Animal Nutrition
  • Livestock Feed Additives
  • Poultry Nutrition
  • Aquaculture Feed
  • Pet Food & Supplements
  • Swine Nutrition
  • Ruminant Nutrition

Regional Analysis

In 2026, Asia-Pacific is expected to maintain its dominant position in the global biotic ingredients market, accounting for 43.1% of total market share. The region benefits from strong domestic consumption across China, Japan, South Korea, and India, supported by a long-established fermented food culture that encourages regular consumption of probiotics, prebiotics, and postbiotics across all age groups. Japan remains a major innovation hub, with Kirin Holdings generating more than 28.0 billion yen from a single postbiotic ingredient series in FY2025, while proprietary surveys showed that over 70.0% of Japanese consumers actively recognize microbiome-related health benefits. South Korean cosmetics manufacturers are also rapidly expanding postbiotic dermo-cosmetic product lines, strengthening both industrial demand and regional manufacturing capacity.

North America is projected to account for 33.1% of the global biotic ingredients market in 2026, making it the second-largest regional market. The region remains highly commercialized due to strong investments in microbiome science, functional beverages, and preventive healthcare products. PepsiCo's USD 1.95 billion acquisition of prebiotic soda brand Poppi and the NIH's USD 215.0 million commitment to the Human Microbiome Project demonstrate growing institutional and corporate confidence in long-term microbiome commercialization. Europe continues to play a strategic role through regulatory leadership and harmonization efforts, including the IPA and Complementary Medicines Australia MoU signed in February 2026. Meanwhile, the Middle East is emerging as a future growth market, although 51.8% of Saudi adults still report limited probiotic knowledge, highlighting significant opportunities for consumer education and early brand expansion.

Key Regions and Countries

North America

• US
• Canada

Europe

• Germany
• France
• The UK
• Spain
• Italy
• Rest of Europe

Asia Pacific

• China
• Japan
• South Korea
• India
• Australia
• Rest of APAC

Latin America

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC
• South Africa
• Rest of MEA

Competitive Landscape

The global biotic ingredients market is moderately consolidated at the top, with a small group of large biosolution and specialty ingredient companies holding disproportionate share through proprietary strain libraries, clinical data portfolios, and global manufacturing infrastructure. The January 2024 merger of Novozymes and Chr. Hansen into Novonesis, a transaction valued at USD 12.3 Billion, created the single largest biotic ingredient entity and reset competitive benchmarks for strain breadth and R&D capacity. Companies outside this tier must compete on specialization rather than scale.

Below the top tier, mid-sized players are pursuing clinical differentiation and channel-specific partnerships to hold position. Organic growth rates of 5.0% to 8.0% within leading companies' human health divisions confirm that the market rewards suppliers with validated claims and application-specific strain data. The emergence of pet health, geriatric nutrition, and cosmeceutical biotics as distinct commercial verticals is creating new sub-market structures where specialized entrants can build leadership positions before larger players direct resources there.

Company Profiles

Novozymes (Chr. Hansen), now operating as Novonesis, holds the strongest market position following the completion of its USD 12.3 billion merger in January 2024. The combined entity brings together Chr. Hansen's human health probiotic strain library and Novozymes' biosolution scale, creating a supplier with unmatched clinical documentation depth and global distribution reach. Novonesis reported 7.0% broad-based organic sales growth in FY2025 with an adjusted EBITDA margin of 37.1%, confirming that the integration is delivering financial performance without margin dilution. Its stated 2030 target of penetrating the USD 13.8 billion probiotic supplement market gives it the clearest long-range commercial roadmap of any player in this space.

dsm-firmenich competes through clinical application breadth and regulatory-first product launches. The company secured regulatory approval for its GLYCARE 2FL HMO prebiotic in India in March 2025, launched a clinically supported synbiotic capsule for IBS relief in July 2025, and introduced a synbiotic supplementation protocol for chronic fatigue syndrome in April 2025. A USD 10.0 million facility modernization at its Schenectady site, completed in March 2026, reflects a deliberate investment in precision delivery technology. Its strategy of securing regulatory clearance in high-growth emerging markets before competitors gives it a first-mover advantage in markets where ingredient approval timelines are long and difficult to replicate quickly.

Key Players

• Novozymes (Chr. Hansen)
• Lallemand Inc.
• Yakult Honsha Co., Ltd.
• Morinaga Milk Industry Co., Ltd.
• Probi AB
• Kerry Group PLC
• BioGaia AB
• OptiBiotix Health PLC
• FrieslandCampina Ingredients
• Beneo GmbH
• BASF SE
• Danone
• Nestlé
• Chr. Hansen
• Kerry Group
• DuPont
• International Flavors & Fragrances
• ADM
• Novonesis
• Glanbia
• Ingredion
• Sabinsa
• Roquette
• Nature's Bounty
• DSM-Firmenich
• Other Key Players

Supply Chain and Value Chain Analysis

The biotic ingredients value chain begins with microbial strain sourcing and fermentation, where the largest share of proprietary value is created. Companies with proprietary strain libraries and fermentation process expertise control the most defensible position in the chain. Downstream, value shifts to encapsulation and stabilization technology, which determines shelf life, bioavailability, and end-use format compatibility. Encapsulation capability is increasingly a B2B contract differentiator, as formulators in pharmaceutical and infant nutrition channels require guaranteed viable cell counts through packaging and distribution.

The biggest supply chain risk sits at the strain stability and cold-chain interface. Live bacterial formats require controlled temperature logistics that add cost and complexity across long international shipping routes. Postbiotics and heat-stable inactivated preparations reduce this risk, which partly explains their commercial acceleration. Kirin Holdings' 200.0% year-on-year overseas volume growth for LC-Plasma ingredients in FY2024 reflects how shelf-stable formats remove logistical friction and unlock distribution at scale in markets where cold-chain infrastructure is unreliable or expensive.

Regulatory Landscape

Regulatory frameworks for biotic ingredients vary significantly by region and application channel, creating uneven market access timelines for suppliers. In India, dsm-firmenich secured approval for its GLYCARE 2FL HMO prebiotic ingredient in March 2025, confirming that human milk oligosaccharide ingredients are now entering regulatory clearance in high-growth emerging markets. This approval matters commercially because India's infant nutrition sector represents one of the largest volume opportunities for HMO ingredients outside Europe and North America. Suppliers without proactive regulatory submissions in these markets will face multi-year delays while approved competitors build distributor relationships and brand equity.

At the international coordination level, the International Probiotics Association and Complementary Medicines Australia signed a regulatory memorandum of understanding in February 2026. This signals a push toward cross-border standard harmonization that will affect how probiotic health claims are substantiated and approved across member markets. For psychobiotic and brain health products, regulatory bodies continue to enforce randomized placebo-controlled trial requirements before approving mental health efficacy claims, creating a high clinical bar that favors well-capitalized suppliers and effectively limits smaller innovators from commercializing in this sub-category without partnership support.

Investment and White Space Analysis

Capital is concentrating around two poles: large-scale consolidation at the top and clinical specialization in emerging sub-categories. The USD 12.3 billion Novozymes and Chr. Hansen merger and PepsiCo's USD 1.95 billion Poppi acquisition confirm that multinationals are committing significant capital to secure biotic ingredient supply and consumer brand positions simultaneously. Novonesis has publicly targeted the EUR 13 billion probiotic supplement market as its 2030 penetration goal, signaling where institutional investment within the sector is directed over the next five years.

The clearest white space sits in geriatric nutrition, companion animal health, and cosmeceutical biotics. All three are commercially active but not yet dominated by any single supplier. Lallemand's Innov'Biome Challenge open innovation funding scheme signals that even established mid-tier players recognize they cannot develop next-generation postbiotic and probiotic microorganisms internally at the pace the market requires. Regions with high growth potential and low current penetration, specifically the Middle East where 51.8% of surveyed adults report low probiotic awareness, represent consumer education opportunities that patient brand investors can convert into durable market share ahead of the category maturing.

Recent Developments

• May 2026: ADM published clinical documentation optimizing postbiotics for target life stages in women's health, strengthening its position in specialized women's nutrition through lifecycle-specific applications and clinically validated formulation frameworks for improved health outcomes across demographics and age groups.
• April 2026: PrecisionBiotics (Novonesis) and Biocodex renewed their strategic partnership for global probiotic expansion, reinforcing international distribution networks and strengthening cross-border reach across key markets in probiotics, gut health, and clinical nutrition segments worldwide expanding long-term collaboration initiatives globally.
• March 2026: dsm-firmenich completed a USD 10 million modernization of its Schenectady facility enhancing precision delivery technologies and expanding advanced formulation capabilities for next-generation probiotic and biotic ingredient manufacturing efficiency and innovation across global supply chains networks optimization program.
• February 2026: Novonesis announced its 2030 strategic target to penetrate the EUR 13 billion probiotic supplement market, focusing on innovation-driven expansion, clinical validation, and large-scale global commercialization across nutrition and health ecosystems worldwide growth strategy execution framework rollout phase.
• February 2026: The International Probiotics Association and Complementary Medicines Australia signed a regulatory MoU to advance cross-border probiotic standard harmonization improving compliance consistency regulatory alignment and global market interoperability across dietary supplement industries framework enhancement initiative implementation phase one.
• September 2025: Kerry Group isolated and launched human milk probiotic strains LC40 and BfM26 designed for early-life nutrition applications supporting infant gut health microbiome development and improved immune system maturation outcomes clinical validation studies ongoing expansion programs globally active.
• July 2025: dsm-firmenich introduced a clinically validated capsule synbiotic mixture targeting Irritable Bowel Syndrome relief combining probiotics and prebiotics for improved gut health outcomes and enhanced digestive system balance in adult populations clinical trials ongoing efficacy assessment results published.
• April 2025: dsm-firmenich launched a three-month synbiotic supplementation protocol targeting chronic fatigue syndrome focusing on microbiome modulation and clinically supported energy immunity and metabolic performance improvement outcomes patient studies demonstrate significant benefits observed across cohorts worldwide clinical adoption increasing.
• January 2025: Debut launched BeautyORB, an AI-powered biotechnology innovation engine for skin microbiome ingredient discovery accelerating development of personalized beauty and dermatological bioactive compounds across cosmetic and wellness industries global adoption increasing rapidly driven by research partnerships innovation ecosystem.

Report Details